Table 4 Univariate and multivariable analysis of prognostic indicators on overall survival and progress-free survival for synchronous metastatic colorectal cancer patients (N = 107)
Parameters | Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis | |||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR | P value | |
Age (years) | 1.160 (0.697–1.929) | 0.568 | 1.561 (0.812–2.999) | 0.182 | 1.160 (0.697–1.929) | 0.568 | 1.561 (0.812–2.999) | 0.182 |
(≥65 vs <65) | ||||||||
Sex | 1.096 (0.661–1.818) | 0.722 | 1.617 (0.790–3.307) | 0.188 | 1.096 (0.661–1.818) | 0.722 | 1.617 (0.790–3.307) | 0.188 |
(Male vs Female) | ||||||||
Location | 0.668 (0.357–1.252) | 0.209 | 0.540 (0.198–1.473) | 0.229 | 0.668 (0.357–1.252) | 0.209 | 0.540 (0.198–1.473) | 0.229 |
Rectum vs Colon | ||||||||
Tumor size | 1.281 (0.784–2.094) | 0.323 | 1.344 (0.683–2.644) | 0.392 | 1.281 (0.784–2.094) | 0.323 | 1.344 (0.683–2.644) | 0.392 |
(≥5 cm vs <5 cm) | ||||||||
Tumor depth | 1.072 (0.333–3.456) | 0.907 | 0.506 (0.107–2.396) | 0.391 | 1.072 (0.333–3.456) | 0.907 | 0.506 (0.107–2.396) | 0.391 |
T3 + T4 vs T1 + T2 | ||||||||
LN metastasis | 0.955 (0.541–1.684) | 0.873 | 0.957 (0.488–1.879) | 0.899 | 0.955 (0.541–1.684) | 0.873 | 0.957 (0.488–1.879) | 0.899 |
Yes vs No | ||||||||
Histology | 1.307 (0.678–2.520) | 0.425 | 1.629 (0.655–4.052) | 0.294 | 1.307 (0.678–2.520) | 0.425 | 1.629 (0.655–4.052) | 0.294 |
PD vs MD + WD | ||||||||
Vascular invasion | 1.092 (0.670–1.779) | 0.724 | 0.826 (0.425–1.605) | 0.573 | 1.092 (0.670–1.779) | 0.724 | 0.826 (0.425–1.605) | 0.573 |
Yes vs No | ||||||||
Perineurial invasion | 1.510 (0.918–2.485) | 0.105 | 1.396 (0.740–2.636) | 0.303 | 1.510 (0.918–2.485) | 0.105 | 1.396 (0.740–2.636) | 0.303 |
Yes vs No | ||||||||
Pre-op CEA (ng/ml) | 1.243 (0.623–2.482) | 0.538 | 1.216 (0.418–3.540) | 0.719 | 1.243 (0.623–2.482) | 0.538 | 1.216 (0.418–3.540) | 0.719 |
≥5/ vs <5 | ||||||||
Post-op CEA (ng/ml) | 0.731 (0.425–1.257) | 0.257 | 0.988 (0.412–2.370) | 0.979 | 0.731 (0.425–1.257) | 0.257 | 0.988 (0.412–2.370) | 0.979 |
≥5 vs <5 | ||||||||
EGFR expression | 0.945 (0.443–2.016) | 0.883 | 0.648 (0.281–1.492) | 0.308 | 0.945 (0.443–2.016) | 0.883 | 0.648 (0.281–1.492) | 0.308 |
Positive vs Negative | ||||||||
KRAS status | 1.167 (0.707–1.925) | 0.546 | 1.051 (0.554–1.992) | 0.879 | 1.167 (0.707–1.925) | 0.546 | 1.051 (0.554–1.992) | 0.879 |
Mut vs WT | ||||||||